NCT07047235

Brief Summary

Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting millions worldwide and causing symptoms such as palpitations, fatigue and breathlessness. It also increases the risk of stroke and heart failure, so effective treatment is essential. A treatment for AF involves catheter ablation, a minimally invasive procedure where problematic areas of the heart are targeted using controlled energy. This is done by passing wires called catheters, through blood vessels at the top of the leg all the way to the heart. However, this isn't effective for everyone and approximately half of patients experience a return of AF despite treatment. In this researcher-led study at St Bartholomew's Hospital , the investigators will use a method called electroanatomical mapping to make a 3D picture of the left atrium, the heart's upper left chamber. To make this picture more detailed, information will be collected - such as how strong electrical signals are (voltage), how fast and in which direction they travel through the heart to describe abnormal areas and areas of scar within the heart. Information will also be gathered about the routes electricity takes and the nerve activity in the heart muscle. These detailed maps will help to understand why AF can continue indefinitely in some people, why ablation works for some people and not others, and improve how ablations are done to make them more effective. All participants will undergo catheter ablation with these mapping methods integrated into the procedure. If AF recurs, patients will be invited for a second ablation targeting specific abnormal areas depending on the amount of scar found. This will be standardised across patients. Patients will be followed for 12 months, with structured visits at 3, 6, 9 and 12 months and 48-hour ECG recorders at 6 and 12 months. By tracking how the heart's structure and electrical behaviour evolve, the aim is to to see if map-guided ablation reduces the need for further procedures, lowers healthcare costs and improves quality of life. Ultimately, this study will provide clear, reproducible insights into AF mechanisms and yield practical guidance so clinicians can predict who will benefit from standard ablation treatment and who may require extra, map-guided treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
52mo left

Started Nov 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Nov 2025Aug 2030

First Submitted

Initial submission to the registry

June 24, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 2, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

November 7, 2025

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 18, 2029

Expected
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 18, 2030

Last Updated

November 18, 2025

Status Verified

November 1, 2025

Enrollment Period

4 years

First QC Date

June 24, 2025

Last Update Submit

November 17, 2025

Conditions

Keywords

ganglionic plexiautonomic remodellingsubstrate remodellingconduction velocity

Outcome Measures

Primary Outcomes (3)

  • Assessment of Electrical, Structural and Autonomic Remodelling in Persistent Atrial Fibrillation

    A primary objective of this study is to delineate the remodelling changes that occur in persistent atrial fibrillation and to utilise these to develop tailored ablation strategies.

    4 years

  • Establish a Predictive Model to Idenitfy Which Patients are Responders to Pulmonary Vein Isolation Alone and Who Will Require Further Tailored Ablation Strategies

    Based on clinical data approximately only 50% of patients with persistent atrial fibrillation who undergo pulmonary vein isolation remain in sinus rhythm. A main aim of the study is to develop a method to identify which patients will respond to pulmonary vein isolation alone and who will require further tailored ablation strategies.

    24 months

  • To Assess if Ablation of Rate Dependent Conduction Velocity Slowing Sites Improves Freedom from Atrial Fibrillation

    All patients who recur after their initial ablation will be invited to undergo a repeat ablation procedure. All patients will undergo ganglionic plexi ablation and reisolation their pulmonary veins. Those who have low voltage zones of more than 30% of their total left atrium will undergo further ablation of rate dependent conduction velocity slowing sites.

    5 years

Secondary Outcomes (1)

  • Develop Personalised Electrical Atrial Models

    5 years

Study Arms (2)

Minimal Low Voltage Zones Group

ACTIVE COMPARATOR

These are patients who've had recurrence of AF after their first ablation and less than 30% of their atria is comprised of low voltage zones. They will undergo autonomic ganglionic plexi site ablation combined with pulmonary vein re-isolation.

Procedure: Pulmonary vein reisolationProcedure: Ganglionic plexi ablation

Significant Low Voltage Zones Group

ACTIVE COMPARATOR

These are patients who've had recurrence of AF after their first ablation and greater than 30% of their atria is comprised of low voltage zones. They will undergo targeted ablation of conduction slowing sites in addition to ganlionic plexi site ablation and pulmonary vein reisolation.

Procedure: Pulmonary vein reisolationProcedure: Ganglionic plexi ablationProcedure: Substrate ablation

Interventions

The pulmonary veins will be checked electrically and further ablation will be undertaken if they are not isolated.

Minimal Low Voltage Zones GroupSignificant Low Voltage Zones Group

Sites where ganglionix plexi have been found will be ablated.

Minimal Low Voltage Zones GroupSignificant Low Voltage Zones Group

Areas of rate dependent conduction velocity slowing will be targeted using cathether ablation

Significant Low Voltage Zones Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able and willing to provide written informed consent
  • Age: 18 years or older
  • Clinical diagnosis: Persistent atrial fibrillation
  • Treatment status: Scheduled to undergo first-time catheter ablation for persistent AF

You may not qualify if:

  • Inability or unwillingness to provide informed consent
  • Under 18 years of age
  • Previous left atrial ablation for AF or other atrial arrhythmias
  • Any clinical contraindications to undergoing AF catheter ablation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St Bartholomew's Hospital

London, United Kingdom

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Shohreh Honarbakhsh, MBBS, MRCP, PhD

CONTACT

Sayed Al-Aidarous, MBBS, MRCP

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: This study is a single-centre, prospective mechanistic cohort investigation with a nested interventional controlled study designed to comprehensively evaluate electrophysiological substrate remodelling and its relationship with procedural outcomes in patients undergoing catheter ablation for persistent AF. Patients already undergoing a first ablation for persistent atrial fibrillation will undergo extensive structural, electrical and autonomic modelling during their index ablation procedure. They will then be followed up for 1 year. Those whose AF recurs will be invited for a repeat procedure in which all patients will undergo reisolation of the pulmonary veins and ganglionic plexi. Those whose atria is comprised of low voltage zones more than 30 will additionally undergo susbtrate modification of rate dependent conduction velocity slowing sites. All these patients will then undergo further follow up for 12 months will be compared to propensity matched controls.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2025

First Posted

July 2, 2025

Study Start

November 7, 2025

Primary Completion (Estimated)

November 18, 2029

Study Completion (Estimated)

August 18, 2030

Last Updated

November 18, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations